News Update Phase 3 Results Published in

News Update Phase 3 Results Published in the New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (Crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer http://ow.ly/2RCHlk

Advertisements